Gingko Bioworks to Acquire Zymergen in Deal Worth $300 Million

Massachusetts-based Gingko Bioworks is aiming to expanding its pipeline of potential drug candidates with the purchase of Zymergen. The deal values the Emeryville, Calif. biotech at $300 million.

Zymergen, which applies genomics and machine learning to develop chemical producing genetically modified organisms, has a pipeline of drug candidates for challenging and difficult-to-drug disease targets.

Bingko Bioworks specializes in using genetic engineering to produce bacteria with applications in a wide range of sectors including industrial chemicals to pharmaceuticals.

The acquisition is expected to be completed by the first quarter of 2023.